MK-8719 is a highly potent and selective OGA inhibitor (EC50 = 52.7 nM) which is a Potential Treatment for Tauopathies. MK-8719 showed excellent CNS penetration that has been advanced to first-in-human phase I clinical trials. 

 

Brand: BCM

 

Target: O-GlcNAcase:ki:7.9 nM

 

In Vivo: MK-8719 has excellent intrinsic potency and selectivity, high CNS exposure, improved Papp, favorable metabolic stability, good pharmacokinetics, and robust pharmacodynamic response.

 

Boiling Point: 431.4±55.0 °C(Predicted)

 

pKa: 12.72±0.70(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol; soluble in Water.

 

Isomeric SMILES: O[C@H]1[C@H](O)[C@@]2([H])N=C(NCC)S[C@@]2([H])O[C@@H]1C(F)F

 

InChIKey: UDQTXCHQKHIQMH-KYGLGHNPSA-N

 

InChI: InChI=1S/C9H14F2N2O3S/c1-2-12-9-13-3-4(14)5(15)6(7(10)11)16-8(3)17-9/h3-8,14-15H,2H2,1H3,(H,12,13)/t3-,4-,5+,6+,8-/m1/s1

 

Attribute
[Chem Name]	(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol
[Synonym]	MK-8719; MK 8719; MK8719
[CAS No.]	1382799-40-7
[MDL No.]	MFCD32263431
[Formula]	C9H14F2N2O3S
[Molecular]	268.28
[Form]	Solid powder
[Storage]	Store at -20°C

Goods Tag